INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice

References

• Takeda Pharmaceuticals America, Inc., Lexington, MA, USA . NINLARO® US prescribing information. ( Revised 5/2022). www.ninlaro.com/prescribing-information.pdf (Accessed 23August2022).
   Google Scholar
• Moreau P , MassziT , GrzaskoNet al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med.374(17), 1621–1634 (2016).
   PubMed Web of Science ®Google Scholar
• Richardson PG , SanMiguel JF , MoreauPet al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J.8(11), 109 (2018).
   PubMed Web of Science ®Google Scholar
• Chari A , RomanusD , PalumboAet al. Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed/refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk.20(1), 8–17; e16 (2020).
   PubMed Web of Science ®Google Scholar
• Hájek R , MinaříkJ , StraubJet al. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncol.17(19), 2499–2512 (2021).
   PubMed Web of Science ®Google Scholar
• Minarik J , PikaT , RadochaJet al. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer21(1), 73 (2021).
   PubMed Web of Science ®Google Scholar
• Terpos E , RamasamyK , MaoucheNet al. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Ann. Hematol.99(5), 1049–1061 (2020).
   PubMed Web of Science ®Google Scholar
• Macro M , HulinC , VincentLet al. Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study. Ann. Hematol.102(8), 2137–2151 (2023).
   PubMed Web of Science ®Google Scholar
• Puig N , AbonourR , DaviesFEet al. Real-world duration of treatment (DOT) with lenalidomide-dexamethasone (Rd)-based regimens in patients (pts) with relapsed/refractory multiple myeloma (RRMM): outcomes from the global INSIGHT MM study. HemaSphere5, 463 (2021). ( Abstract EP985).
   Google Scholar
• Costello C , DaviesFE , CookGet al. INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Future Oncol.15(13), 1411–1428 (2019).
   PubMed Web of Science ®Google Scholar
• Ludwig H , TerposE , MateosM-Vet al. Effectiveness and safety of ixazomib-based therapy in relapsed/refractory multiple myeloma (MM) outside of a clinical trial: final analysis of the ’use via early access to ixazomib’ (UVEA IXA) study. HemaSphere5, 468 (2021). ( Abstract EP994).
   Google Scholar
• Leleu X , BoccadoroM , LeeHCet al. The INSURE study (INSIGHT MM, UVEA-IXA, REMIX): a pooled analysis of relapsed/refractory multiple myeloma (RRMM) patients treated with ixazomib-lenalidomide-dexamethasone (IRd) in routine clinical practice. Presented at: the 63rd Annual Meeting of the American Society of Hematology (ASH) 2021.Atlanta, USA, Poster 2701, 11–14 December 2021.
   Google Scholar
• Palumbo A , BringhenS , MateosM-Vet al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood125(13), 2068–2074 (2015). Erratum in: Blood 12, 1213 (2016). Erratum in: Blood 128, 1020 (2016).
   PubMed Web of Science ®Google Scholar
• Facon T , DimopoulosMA , MeulemanNet al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia34(1), 224–233 (2020).
   PubMed Web of Science ®Google Scholar
• Chari A , RomanusD , LuptakovaKet al. Duration of therapy (DOT) and time to next therapy (TTNT) of bortezomib, carfilzomib and ixazomib combinations with lenalidomide/dexamethasone (VRd, KRd, IRd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): clinical practice in the United States vs clinical trial experience. Blood130, 1818 (2017).
   Google Scholar
• Walker MS , HermsL , MillerPJE. Performance of time to discontinuation and time to next treatment as proxy measures of progression-free survival, overall and by treatment group. J. Clin. Oncol.38(Suppl. 15), e19135 (2020).
   Google Scholar
• Bakırtaş M , DalMS , YiğenoğluTNet al. Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey. J. Chemother.35(6), 563–569 (2023).
   PubMed Web of Science ®Google Scholar
• Varga G , NagyZ , DemeterJet al. Real world efficacy and safety results of ixazomib lenalidomide and dexamethasone combination in relapsed/refractory multiple myeloma: data collected from the Hungarian ixazomib named patient program. Pathol. Oncol. Res.25(4), 1615–1620 (2019).
   PubMed Web of Science ®Google Scholar
• Yong K , DelforgeM , DriessenCet al. Multiple myeloma: patient outcomes in real-world practice. Br. J. Haematol.175(2), 252–264 (2016).
   PubMed Web of Science ®Google Scholar
• Hari P , RomanusD , PalumboAet al. Prolonged duration of therapy is associated with improved survival in patients treated for relapsed/refractory multiple myeloma in routine clinical care in the United States. Clin. Lymphoma Myeloma Leuk.18(2), 152–160 (2018).
   PubMed Web of Science ®Google Scholar
• Mateos MV , RichardsonPG , DimopoulosMAet al. Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am. J. Hematol.90(4), 314–319 (2015).
   PubMed Web of Science ®Google Scholar
• Jimenez-Zepeda VH , DugganP , NeriP , TayJ , BahlisNJ. Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma. Ann. Hematol.96(3), 431–439 (2017).
   PubMed Web of Science ®Google Scholar
• Atrash S , Thompson-LeducP , TaiMHet al. Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study. BMC Cancer21(1), 1207 (2021). Erratum in: BMC Cancer 21, 1291 (2021).
   PubMed Web of Science ®Google Scholar
• Blonde L , KhuntiK , HarrisSB , MeizingerC , SkolnikNS. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Adv. Ther.35(11), 1763–1774 (2018).
   PubMed Web of Science ®Google Scholar
• Prasad V , BilalU. The role of censoring on progression free survival: oncologist discretion advised. Eur. J. Cancer51(16), 2269–2271 (2015).
   PubMed Web of Science ®Google Scholar
• Chari A , RichardsonPG , RomanusDet al. Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. Expert Rev. Hematol.13(4), 421–433 (2020).
   PubMed Web of Science ®Google Scholar